Back to Journals » OncoTargets and Therapy » Volume 10

Anticancer activities of epigallocatechin-3-gallate against cholangiocarcinoma cells

Authors Kwak TW, Park SB, Kim HJ, Jeong YI, Kang DH

Received 9 May 2016

Accepted for publication 26 August 2016

Published 22 December 2016 Volume 2017:10 Pages 137—144

DOI https://doi.org/10.2147/OTT.S112364

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati

Tae Won Kwak,1,* Su Bum Park,2,* Hyun-Jung Kim,3 Young-IL Jeong,4 Dae Hwan Kang1,2

1Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, 2Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Gyeongnam, 3Genewel Co. Ltd. Seongnam, Gyeonggi-do, 4Biomedical Research Institute, Pusan National University Hospital, Pusan, Republic of Korea

*These authors equally contributed to this work

Purpose: Epigallocatechin-3-gallate (EGCG) is an antioxidant agent derived from green tea. Because it has chemopreventive and anti-invasive effect against various cancer cells, EGCG can be used to inhibit proliferation and invasion of cholangiocarcinoma (CCA) cells.
Methods: The anticancer effects of EGCG were studied using human CCA cells (HuCC-T1). Apoptosis was analyzed by Western blotting. Invasion and migration of cancer cells were assessed with Matrigel® and wound healing assays. An animal tumor xenograft model of HuCC-T1 was used to study the in vivo antitumor activities of EGCG.
Results: EGCG effectively inhibited the growth of HuCC-T1 cells with no adverse effects on the viability of 293T cells. EGCG induced apoptotic cell death at 5 µg/mL concentration. It inhibited the expression of mutant p53 and induced apoptotic molecular signals such as Bax/Bcl-2, Caspase, and cytochrome C. Furthermore, EGCG dose-dependently inhibited the activity of matrix metalloproteinase (MMP)-2/9, invasion, and migration. In the animal tumor xenograft model of HuCC-T1 cells, EGCG was subcutaneously administered beside the tumor for local treatment. EGCG efficiently inhibited growth of the tumor and suppressed carcinogenic molecular signals such as Notch1, MMP-2/9, and proliferating cell nuclear antigen.
Conclusion: EGCG induced apoptosis of cancer cells without adverse effects on normal cells. EGCG inhibited growth, invasion, and migration of HuCC-T1 cells. We suggest EGCG as a promising candidate for local treatment of CCA.

Keywords: epigallocatechin-3-gallate, cholangiocarcinoma, matrix metalloproteinases-2, invasion, thermosensitive hydrogel

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Vorinostat-eluting poly(DL-lactide-co-glycolide) nanofiber-coated stent for inhibition of cholangiocarcinoma cells

Kwak TW, Lee HL, Song YH, Kim C, Kim JS, Seo SJ, Jeong YI, Kang DH

International Journal of Nanomedicine 2017, 12:7669-7680

Published Date: 17 October 2017

Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery

Lee SJ, Jeong YI, Park HK, Kang DH, Oh JS, Lee SG, Lee HC

International Journal of Nanomedicine 2015, 10:5489-5503

Published Date: 28 August 2015

Release of tissue inhibitor of metalloproteinase-2 from alginate microcapsule encapsulating genetically engineered cells

Kim YS, Jeong YI, Jin SG, Pei J, Wen M, Kim IY, Moon KS, Jung TY, Ryu HH, Jung S

International Journal of Nanomedicine 2013, 8:4351-4359

Published Date: 6 November 2013

Dextran-b-poly(L-histidine) copolymer nanoparticles for pH-responsive drug delivery to tumor cells

Hwang JH, Choi CW, Kim HW, Kim DH, Kwak TW, Lee HM, Kim CH, Chung CW, Jeong YI, Kang DH

International Journal of Nanomedicine 2013, 8:3197-3207

Published Date: 21 August 2013

Doxorubicin-incorporated polymeric micelles composed of dextran-b-poly(DL-lactide-co-glycolide) copolymer

Jeong YI, Kim DH, Chung CW, Yoo JJ, Choi KH, Kim CH, Ha SH, Kang DH

International Journal of Nanomedicine 2011, 6:1415-1427

Published Date: 6 July 2011